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ABSTRACT
The prevalence of herpes simplex virus (HSV) infection globally is high, and although
there is no cure for it, the antiviral drug acyclovir is used to alleviate symptoms. There
are two types of HSV: HSV-1, which typically infects the oral area, and HSV-2, which is
associated with genital infections. A mother who carries the infection may transmit it to a
neonate in different ways, most commonly via vaginal delivery in the presence of active
lesions. There are three types of HSV disease that affect newborns: skin, eyes or mouth
(SEM) disease, central nervous system (CNS) disease, or disseminated disease. The
purpose of this study was to examine the long-term effects of the infection and the
treatment used in neonates infected with HSV. Data collection consisted of original case
reports published in Medline, CINHAL, and Google Scholar. Two case reports were
found, and this narrative review compares the cases, which report recurrences and
outcomes of HSV infection identified in the three databases. Both cases were consistent
with recurrence of CNS disease, and one showed signs of a slight developmental delay
that may have been related to the CNS insult.
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INTRODUCTION
Herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2) are double-stranded,
DNA viruses commonly transmitted sexually leading to infections that can affect the
oral (HSV-1) or genital (HSV-2) areas. Although no cure has been found yet, the
infection can be treated with the antiviral drug acyclovir. The treatment of a first
outbreak in adults consists of 400 mg of acyclovir orally, three times a day for seven to
ten days (Whitley, 2007). For adults with recurrent outbreaks, meaning that they have
had an initial treatment, the drug dose is 400 mg taken orally twice a day for seven
days. This is important to know because it is the treatment that a mother who has been
infected would receive to minimize the duration of outbreaks and to prevent recurrent
viral shedding. It is recognizable when an expectant mother has an outbreak because
lesions appear in the infected areas. A typical lesion is an ampulla or blister that may
bleed or ooze a limited amount of fluid, and the outbreak area may present with pruritus
or a burning sensation.
Adults infected with HSV, regardless if it is type 1 or 2, may transmit the virus to
a newborn in three different ways. First, it may be transmitted during birth through the
vaginal canal with an active outbreak. Second, the neonate may be exposed to HSV
when the amniotic sac ruptures. Third, a caregiver with an active infection may transmit
it to the newborn. A baby born to a mother with a first-time lesion has 25% to 60% risk
of infection, whereas a baby born to a mother who has a recurring infection is less likely
to be infected (i.e., 2% rate) (Harris & Holmes, 2017). It has been recommended that
pregnant women who are aware of their infection, even if they do not have lesions at
1

the time, start acyclovir therapy at 36 weeks of gestation (Harris & Holmes, 2017). This
therapeutic approach does not prevent virus transmission, rather, it decreases the
number of outbreaks that the mother may have when getting closer to labor and birth.
If the newborn is infected with HSV during birth, they may present the first signs
and symptoms between the moment of birth up to two months after. Some of the
symptoms, such as fever and infection, may resemble other conditions and may be
misdiagnosed as a bacterial infection. Assuming that both the provider and mother are
aware of the mother’s existing infection, the first step after the baby is born is to test the
newborn for HSV within 24 hours of birth (Harris & Holmes, 2017). Nevertheless, there
are cases were the mother is unaware of her infection because it has been dormant
until labor. If this is the case and the neonate show signs of infection, they must be
tested for HSV as well.
A neonatal HSV infection may manifest in three ways. First, when the infection
involves the skin, eyes, and mouth (SEM), it usually manifests around the fifth to
eleventh day of life, with lesions around the mouth and the skin, without involvement of
the central nervous system (CNS) or the internal organs. Just like in adults, the therapy
of preference to treat this virus is acyclovir, nevertheless the route of administration and
the strength of the dosage is different. For neonates, the treatment of HSV is
intravenous acyclovir 60 mg/kg/day every 8 hours, three times a day, for 14 days
(Pinninti et al, 2018). If the SEM disease is not treated in time or if it is mistreated or
mistaken for a bacterial infection, it may progress and develop into CNS or
disseminated disease. Health care providers try to avoid this progression because out
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of the three types of disease, SEM disease is the least dangerous and aggressive
(Harris & Holmes, 2017).
A second form of the disease is the CNS disease, which generally manifests
around the eighth to seventeenth day of life. Before manifestation of this form of the
disease, the neonate is most likely asymptomatic, unless the disease arises from an
untreated SEM disease, or the mother was unaware that she is a carrier of the HSV
virus, so the baby was not tested during their first 24 hours of life. Symptoms mirror
neonatal bacterial infections, therefore a test on the cerebrospinal fluid (CSF) must be
conducted to verify if the neonate has indeed a bacterial or a viral infection. According
to Harris and Holmes, “a total of 50% of neonates who are diagnosed with a localized
CNS disease will die, and the ones [who] survive will have severe neurologic sequelae”
(2017, p. 89). Just like in the SEM disease, the treatment for the CNS disease is
acyclovir 60 mg/kg/day three times a day, but in this case, therapy duration is 21 days.
Last, neonatal HSV infection may manifest as disseminated disease, which
involves various internal organs, such as the lungs, liver, CNS, and/or adrenal glands
(Pinninti et al, 2018). Typically, neonates with disseminated disease appear with fever,
renal and/or lung failure, and may experience disseminated intravascular coagulopathy
(Harris & Holmes, 2017). It has been shown that “nearly 30% of newborns with
disseminated disease die even with treatment” (Harris & Holmes, 2017, p.89). As with
the previous forms of neonatal HSV disease, newborns who have been infected are
treated with intravenous acyclovir 60 mg/kg/day every 8 hours for 21 days.
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Herpes simplex virus infection may be asymptomatic for years or may manifest
with symptoms immediately after the infection. If a pregnant woman knows that she has
an HSV-2 infection or if her healthcare professional suspects the infection, the newborn
must be tested for HSV within 24 hours after birth. If the neonate tests positive, they
must be treated in a timely manner. Some studies “recommend giving oral acyclovir
therapy at a dose of 300 mg three times a day for six months after completion of
[intravenous] therapy” (Bhatta et al., 2018, p. 690). Nevertheless, it has been shown
that long-term use of acyclovir can lead to neutropenia, which can lead to increased
vulnerability to other infections. Neutropenia may be self-limited following treatment
with acyclovir but monitoring of neutrophil count is still recommended during treatment
(Whitley, 2007).
After reviewing the different types of neonatal syndromes associated with HSV
infection and understanding the treatment for infected adults and neonates, it is evident
that there is a gap in the literature for the long-term effects of both the neonatal HSV
infection and its therapy. Thus, this study aims to describe the long-term effects
reported for neonatal HSV infection and its treatment in children with congenital HSV
infection.
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METHODS
Study design
A narrative literature review was the design of choice for this study to critically
review the literature on neonatal HSV infection and its long-term outcomes. In this
study, congenital herpes infection was defined as a newborn who showed the presence
of the virus between the fifth and seventeenth days of life. This study focused on finding
the effects of the HSV infection in patients who were initially diagnosed within their first
month of life.
Data sources and search strategy
Data search was conducted among original publications in English without
date limits in PubMed, the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), and Google Scholar. Table 1 showcases the keywords and phrases
related to HSV that were used to conduct multiple searches.
Table 1. Keywords used for data search
Search on PubMed and CINAHL
Neonatal and HSV and effects
Herpes simplex virus and neonatal and longterm effects
Herpes simplex virus and mother-to-child
transmission
HSV and neonatal prognosis or outcome
Congenital herpes and treatment or
intervention and effects or consequences

Search on Google Scholar
Adult survivors of herpes at birth
Antiviral therapy for HSV
Neonatal viral simplex infection and acyclovir
Incidence of congenital hsv infection

Study selection
Articles were selected if they contained original reports of long-term outcomes of
neonatal HSV infection or therapy. Articles that did not report original data or that did
not discuss the long-term outcomes of the infection or therapy were discarded.
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Data extraction
Articles meeting the inclusion criteria were retrieved and read in full by the author.
After reviewing the reports, key demographic variables on the cases were extracted in a
matrix, namely: age, gender, time of initial HSV infection, HSV type, course of treatment
received, and long-term outcomes.
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RESULTS
The purpose of this study was to investigate the long-term side effects of
neonatal HSV infection and treatment. The search in all three databases identified four
records matching the keyword search, published between 2009 and 2017. Two
publications were excluded: one was a commentary on the dearth of studies on the
long-term outcomes of neonatal HSV infection (Melvin et al., 2015) and one was a
review on the treatment of neonatal HSV infection, without reporting long-term
outcomes (Jones et al., 2009). Thus, two studies reporting original data remained in this
analysis (Henderson et al., 2015; Kato et al., 2017). Table 2 presents the key findings
extracted from these reports, followed by a summary of each case.
Table 2. Summary of the characteristics of the case reports reviewed.
Study
Country
Sex
Age at initial infection
Treatment at initial infection
Type of virus and disease
Age at recurrence
Treatment at recurrence
Long-term outcomes reported

Kato et al., 2015
Japan
Boy
12 days old
Intravenous acyclovir 20
mg/kg every 8h for 21 days
HSV-2 with CNS disease
7 months old
Intravenous acyclovir 15
mg/kg every 8h for 21 days
Delayed in development

Henderson et al., 2017
Not specified
Girl
10 days old
Intravenous acyclovir 60 mg/kg per
day for 21 days
HSV-2 with CNS disease
7 years old
Intravenous acyclovir for 21 days
Not specified

Case report 1 (Kato et al., 2015)
A 12-day-old boy was vaginally delivered by a mother with previous history of
HSV-1, without history of HSV-2. For his first 11 days of life, he showed no signs or
symptoms of an infection (no fever, lesions, vomiting, etc.) All laboratory results for the
boy were within range. Nevertheless, a magnetic resonance imaging (MRI) showed
brain hemorrhage. After a spinal tap, the baby was diagnosed with neonatal HSV

7

infection with CNS disease. The treatment prescribed was intravenous acyclovir
20 mg/kg per dose every eight hours for 21 days. After completing the intravenous
treatment, the blood and CSF laboratory results came back negative for HSV infection
and the patient was prescribed oral valacyclovir for six months.
Nevertheless, he was brought back to the hospital with fever 14 days after
completing the oral therapy. A spinal tap showed presence of HSV in the cerebrospinal
fluid (CSF), so he was started once more on intravenous acyclovir for 21 days.
Following this, he was administered oral therapy for a year. When the second oral
suppressive therapy ended, a standardized developmental test showed slight delay in
his development. No recurrences were reported proceeding the last round of oral
therapy, this after being followed up for a year.
Case report 2 (Henderson et al, 2017)
A 7-year-old girl presented with headaches, dizziness, and signs of vomiting. She
had a history of neonatal HSV-2 infection with CNS disease at 10 days of age. After the
diagnosis, she received intravenous acyclovir for 21 days, and after this, she followed
an oral therapy of acyclovir for six months. The patient did not show any symptoms of
HSV infection until seven years later.
During the recurrent episode, all laboratory results for HSV infection were within
range, except for the CSF test, which was positive for HSV-2. This confirmed a
diagnosis of HSV-2 meningitis. She received intravenous acyclovir for 21 days,
resolving her symptoms by the third day on treatment. After completing the treatment,
laboratory results were negative for HSV-2 infection, and she was discharged with oral
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acyclovir for 12 months. After completing the oral treatment for a year, she showed no
recurrence.
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DISCUSSION
The aim of this narrative review was to describe reports on the long-term
outcomes of neonatal HSV treated with acyclovir. Only two case reports met the
inclusion criteria and were included. Both cases reported recurrence of HSV in patients
previously diagnosed and treated for HSV with CNS involvement during the neonatal
period. Neither case ever showed signs of skin lesions or rashes suggesting that the
CNS disease did not progress from SEM disease. Treatment was the same for both
cases when they were first diagnosed (i.e., intravenous acyclovir for 21 days), followed
by antiviral suppressive therapy of oral valacyclovir or acyclovir for six months.
One of the differences between the two case reports was the time between the
recurrences. While the male patient had a recurrence approximately seven months after
the initial insult, the female patient experienced an interval of seven years between
outbreaks. One potential reason for this difference is that the male patient was treated
with oral valacyclovir as the suppressive therapy, and the female patient was prescribed
acyclovir for the same purpose. Nevertheless, both case reports explain that a
shortened course of therapy can be a big factor in the sequelae of the disease,
explaining why after the intravenous therapy, there’s an oral suppressive therapy for a
longer period.
Another of the differences found was the age of recurrence. The boy had a CNS
recurrence at 7 days of age, whereas the girl had a CNS recurrence at age 7. Time to
recurrence has long been reported as highly unpredictable (Corey, 1988), which is
consistent with the disparity in the age of recurrence in the two cases at hand.
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Finding only two cases greatly limits the extrapolation and analyses of long-term
outcomes after an initial neonatal HSV infection. Several reasons might be behind this
phenomenon, including efficacy of acyclovir treatment, changes in HSV disease
prevalence, and the role of stigma in disclosing and treating sexually transmitted
infections. These potential reasons for a dearth in the long-term outcomes reported are
discussed next.
Efficacy of the treatment
For the initial treatment of both HSV-1 and HSV-2 in neonates, intravenous
administration of the antiviral drug acyclovir is prescribed. This drug has been available
for medical use for over three decades and it has showed outstanding efficacy for
treating an initial viral infection in neonates, as it not only reduces the days with active
infection, but also lowers the odds of recurrence and mortality among newborns
(Kimberlin & Whitley, 2007). Previously, HSV infection was treated with vidarabine, and
although both vidarabine and acyclovir were effective, vidarabine required high doses,
making acyclovir the treatment of choice, not only because it requires a lower dose, but
it is also easier to administer. Despite its ability to improve symptoms and reduce the
days of active infection, acyclovir is not a cure
In the first case report (Kato et al., 2015), the boy was treated with valaciclovir, a
prodrug of acyclovir, as the oral suppressive therapy after the first intravenous treatment
with acyclovir. A study showed that both acyclovir and valaciclovir have the same
effects when used as oral suppressive therapy (Miserocchi et al., 2007); however,
Gupta et al. (2004) report that valacyclovir is better absorbed. Nevertheless, considering
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the results of the two case reports in which valacyclovir was used for the suppressive
therapy post initial outbreak in the male patient and acyclovir was used as suppressive
therapy for the female patient, one might speculate acyclovir is more effective for this
purpose because the female patient did not have a recurrence for seven years, while
the male patient treated with valacyclovir, had a second outbreak two weeks after the
termination of the initial suppressive oral therapy. This is merely speculation as a
conclusion cannot be drawn based on two case studies. A well-powered, long-term
randomized controlled clinical trial comparing the use of acyclovir versus valacyclovir
would be needed to make this conclusion.
It is important to point out that, before acyclovir was discovered to work against
the HSV infection, a great percentage of patients with congenital herpes died within their
first year of life. Based on the effectiveness of acyclovir in treating an initial HSV
infection in neonates, one might infer that there may be a long-term benefit of this drug
in terms of decreasing the chance of having an outbreak later in life, as was the case in
the female case report. Nevertheless, this too is speculation and would need to be
borne out by a long-term clinical trial.
Change in HSV incidence rate
Before acyclovir treatment was commonplace, for every five pregnant women not
infected with HSV-2 there was one pregnant woman with the infection (Whitley et al,
2007). Even though the neonate may acquire the infection from someone with either
genital or oral herpes, the most common mechanism reported is vaginal delivery
occurring when an active outbreak is present in the mother (James & Kimberlin, 2015).
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It is important to point out that, according to the National Center for Health Statistics
(NCHS), from 2000 (18.0%) to 2016 (12.1%), the incidence of HSV-2 infection in ages
14-49 has decreased by almost 6% (McQuillan et al., 2018). Whereas the incidence of
HSV-1 infection among the same age group and time interval decreased by about 11%,
going from 59.4% to 48.1% (McQuillan et al., 2018). The declining incidence may be the
result of education about the importance of using protection during sexual activity and
knowing the medical history of the sexual partners to avert sexually transmitted
infections.
The role of stigma
It is not a secret that sexually transmitted infections (STIs) are stigmatized
worldwide resulting in patients being marginalized and shamed for their sexual history.
Researchers believe that, due to potential shame, parents may be reluctant to speak out
about their STIs and how they transmitted it to their babies (Melvin et al., 2015). It is
possible that mothers omit informing their child about their past medical history due to
the possible guilt they may feel. Expectant mothers with HSV infections may fail to tell
their healthcare provider about their own medical record, again, for the possible shame
they may feel. Because of this, it is presumed that parents would not enroll their children
in studies that aim to research the long-term outcomes of this infection in neonates.
The aforementioned implications of efficacy and stigma may explain, at least
partially, why there are not enough follow-up studies on children after the initial
diagnosis of neonatal HSV.
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Possible transmission to future sexual partners
Viral infections like HSV do not have a cure as the virus continues to reside in the
body. Even though babies get treated after initial diagnosis, it is known that the virus
stays latent in the dorsal ganglia of the spinal cord, and it has the potential to recur at
any time. HSV infection may remain dormant for many years and may never show signs
or symptoms of infection in the future. Whether HSV infection acquired as a neonate
can be transmitted to a future sexual partner is unknown, so researchers cannot confirm
or eradicate the question of possible partner-to-partner transmission of neonatally
acquired HSV infection.
Study limitations
There are several limitations of the investigation undertaken to explore the longterm effects of neonatal HSV infection and treatment. The dearth of research and case
reports in the literature presented the greatest limitation to answer the research
questions, with only two case reports identified from the databases used for this
research. The lack of reports may be due in part to reporting and subject bias. Narrative
reviews like this one depend on previous publications, but there is a possibility that
clinicians are not reporting recurrences of neonatal herpes infections. This may be due
to their busy schedules or their lack of knowledge about the current gap in the literature
on long-term outcomes of neonatal HSV infection. It is also possible that asymptomatic
HSV infection contracted perinatally may eventually be manifested later in life.
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CONCLUSION
The signs and symptoms of neonatally acquired HSV infection are treatable with
antiviral therapy; however, recurrence of symptoms, as has been documented in two
published case reports, is possible, with the length of time between the initial and
subsequent outbreaks varying between the two cases. Triggers that may cause
recurrence are yet to be identified, as is the true frequency with which subsequent
outbreaks occur. Based on the documented cases identified for this project, one
difference that may account for variability in the length of time from the initial to
subsequent outbreak might be related to the choice of drug therapy; however, there is
purely speculation that needs to be borne out through additional research. Even though
there is not much literature on the inquiry of this project, the fact that long-term sequelae
were documented in the two case reports where CNS disease recurred, suggests the
need for surveillance, reporting, research, and strategies for prevention. Future studies
might include an observational study that systematically reviews and compares all
cases of neonates acquiring HSV infection during the perinatal period through
adolescence or adulthood. Although this type of study could provide data needed to
support the need for further investigation using a more rigorous study design, a
drawback to this approach would be the duration of time needed to identify possible
patterns or associations. Given enough evidence to support the idea that differences in
therapeutic approaches might be related to the duration between initial and subsequent
occurrence, a randomized clinical trial comparing treatment approaches would be in
order and would provide more concrete evidence to support or refute this hypothesis.
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